Evaluation of Plasmodium vivax Cell-Traversal Protein for Ookinetes and Sporozoites as a Preerythrocytic P. vivax Vaccine

Alves, E; Salman, A; Leoratti, F; Lopez-Camacho, C; Viveros-Sandoval, M; Lall, A; El-Turabi, A; Bachmann, M; Hill, A; Khan, S; Reyes-Sandoval, A

Journal article

Evaluation of Plasmodium vivax Cell-Traversal Protein for Ookinetes and Sporozoites as a Preerythrocytic P. vivax Vaccine

Abstract:: Four different vaccine platforms each targeting the human malaria parasite Plasmodium vivax cell- traversal protein for ookinetes and sporozoites (PvCelTOS) were generated and assessed for protective efficacy. These platforms consisted of a recombinant chimpanzee adenoviral vector ChAd63-PvCelTOS (Ad); a recombinant MVA-PvCelTOS (MVA); a bacteriophage Qβ-PvCelTOS virus-like particle (VLP); and recombinant PvCelTOS protein expressed in eukaryotic HEK293T cells (protein). Inbred BALB/c and outbred CD-1 mice were immunized using the following prime/boost regimens: Ad-MVA, Ad-VLP and Ad-protein. Protective efficacy against sporozoite challenge was assessed after immunization using a novel chimeric rodent Plasmodium berghei parasite. This chimeric parasite (Pb-PvCelTOS) expresses P. vivax CelTOS in place of the endogenous P. berghei CelTOS and produces fully infectious sporozoites. A single A2 immunization in BALB/c and CD-1 mice induced anti-PvCelTOS antibodies which were boosted efficiently using MVA, VLP or protein immunization. High frequencies of PvCelTOS specific IFN-γ and TNF-α producing CD8+ 44 T-cells were induced by all prime/boost regimens in BALB/c but not in CD-1 mice; in CD1 mice they were only marginally increased after boosting with MVA. Despite the induction of anti-PvCelTOS antibodies and PvCelTOS-specific CD8+ 46 T-cell responses, only low protective efficacy against challenge with Pb-PvCelTOS sporozoites was obtained, using any immunization strategy. In BALB/c mice no immunization regimes provided significant protection against a Pb-PvCelTOS chimeric sporozoite challenge. In CD1 mice modest protective efficacy was observed using the Ad-Protein vaccination regimen against challenge with chimeric P. berghei sporozoites expressing either PvCelTOS or P. falciparum CelTOS.

Publication status:: Published

Peer review status:: Peer reviewed

Actions

Email

Email this record

Send the bibliographic details of this record to your email address.

Your Email
Please enter the email address that the record information will be sent to.

-
Your message (optional)
Please add any additional information to be included within the email.
Cite

Cite this record

APA Style

Alves, E., Salman, A., Leoratti, F., Lopez-Camacho, C., Viveros-Sandoval, M., Lall, A., El-Turabi, A., Bachmann, M., Hill, A., Khan, S., & Reyes-Sandoval, A. (2017). Evaluation of Plasmodium vivax Cell-Traversal Protein for Ookinetes and Sporozoites as a Preerythrocytic P. vivax Vaccine. Clinical and Vaccine Immunology, 24(4), e00501–16.

MLA Style

Alves, E., et al. “Evaluation of Plasmodium Vivax Cell-Traversal Protein for Ookinetes and Sporozoites as a Preerythrocytic P. Vivax Vaccine.” Clinical and Vaccine Immunology, vol. 24, no. 4, American Society for Microbiology, 2017, pp. e00501–16.

Chicago Style

Alves, E, A Salman, F Leoratti, C Lopez-Camacho, M Viveros-Sandoval, A Lall, A El-Turabi, et al. 2017. “Evaluation of Plasmodium Vivax Cell-Traversal Protein for Ookinetes and Sporozoites as a Preerythrocytic P. Vivax Vaccine.” Clinical and Vaccine Immunology 24 (4): e00501–16.
Share
Print